Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs BMS 817399 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 17 Mar 2020 Results (n=978) of retrospective, observational analysis from seven rheumatoid arthritis clinical studies: H9BMCBCDM, H9BMCBCDO, H9BMCBCDV, IM126004, IM119015, IM101029, M10261 geographical information (from Asia, Latin America, RFEE, USA, and Western Europe) assessing regional differences in adverse event rates and disease activity were published in the Rheumatology
- 17 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2013 Actual initiation date changed from Feb 2011 to Sep 2011 as reported by ClinicalTrials.gov.